Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom

• Príomhchruthaitheoirí: Pamella G. Gutierres (Údar), Diego R. Pereira (Údar), Nataly L. Vieira (Údar), Lilian F. Arantes (Údar), Nelson J. Silva (Údar), Kristian A. Torres-Bonilla (Údar), Stephen Hyslop (Údar), Karen Morais-Zani (Údar), Rosa M. B. Nogueira (Údar), Edward G. Rowan (Údar), Rafael S. Floriano (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by snake venoms. In this study, we examined the ac...